<DOC>
	<DOCNO>NCT02132468</DOCNO>
	<brief_summary>This study investigate safety , symptom biomarker response subject biopsy-proven well-differentiated , low-to-intermediate-grade , unresectable , metastatic PNETs GI-NETs elevate biochemical marker relapse receive prior standard care therapy , include octreotide , chemotherapy target therapy .</brief_summary>
	<brief_title>A Ph 2 Study Fosbretabulin Subjects w Pancreatic Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers</brief_title>
	<detailed_description>Subjects enrol PNET/GI-NET study ( OX4218s ) receive weekly dosing fosbretabulin 3 cycle approximately 9 week .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>Ability read , understand provide write consent participate study Age ≥ 18 year Biopsyproven welldifferentiated , lowtointermediategrade PNET GINET elevate ( &gt; ULN ) biomarkers ( serotonin , 5hydroxyindoleacetic acid ( 5HIAA ) , chromogranin A ( CgA ) , neurokinin A , neuronspecific enolase ( NSE ) ) Life expectancy &gt; 12 week Must receive may still receive one therapy include octreotide serotonin synthesis inhibitor ( SSI ) somatostatin analogue Confirmed progressive disease within 18 month enrollment study Recovered prior radiation therapy surgery Eastern Cooperative Oncology Group ( ECOG ) performance score 02 Absolute neutrophil count ( ANC ) ≥ 1,500/µL ( without growth factor ) Platelet count ≥ 100,000/µL Adequate renal function evidence serum creatinine ≤ 2.0 mg/dL ( 177 µmol/L ) Adequate hepatic function : serum total bilirubin ≤ 2X great upper limit normal ( ULN ) ( ≤ 3X ULN subject liver metastasis ) , AST ( Aspartate aminotransferase ) /ALT ( Alanine aminotransferase ) ≤ 2X ULN local reference lab ( ≤ 5X ULN subject liver metastasis ) Disease assess ( evaluable ) imaging ( CT , MRI , PET , radionuclide image image modality ) Women childbearing potential well fertile men partner must use effective method birth control Inadequately control hypertension define BP &gt; 150/100 mm Hg despite medication Prior history hypertensive crisis hypertensive encephalopathy Recent history ( within 6 month start screen ) unstable angina pectoris pattern , myocardial infarction ( include nonQ wave MI ) , NYHA ( New York Heart Association ) Class III IV Congestive Heart Failure ( CHF ) Subjects clinical evidence carcinoidinduced heart disease History prior cerebrovascular accident ( CVA ) , include transient ischemic attach ( TIA ) Known central nervous system ( CNS ) disease except treated brain metastasis History torsade de pointes , ventricular tachycardia fibrillation , pathologic sinus bradycardia ( &lt; 60 bpm ) , heart block ( exclude 1st degree block , PR interval prolongation ) , congenital long QT syndrome new ST segment elevation depression new Q wave ECG Corrected QT interval ( QTc ) &gt; 480 msec Ongoing treatment drug know prolong QTc interval , include antiarrhythmic medication ( stable regimen antidepressant selective serotonin reuptake inhibitor ( SSRI ) class allow ) ) Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Significant vascular disease recent peripheral arterial thrombosis Known intolerance hypersensitivity fosbretabulin History solid organ transplant bone marrow transplant Any intercurrent medical condition , include mental illness substance abuse , deem Investigator likely interfere subject 's ability sign inform consent , cooperate participate study , interfere interpretation result High grade poorly differentiate NET NET tumor PNET GINET No elevate biomarker ( &gt; ULN ) follow Received regional hepatic infusion therapy within 6 month enrollment ( RFA allow &gt; 6 month prior enrollment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PNET</keyword>
	<keyword>GI-NET</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>carcinoid</keyword>
</DOC>